In 2006, DIA was among the first organizations to recognize the importance of patient involvement in drug development and launched its first Patient Fellowship Program. Since then, the role patients can play in therapeutic product R&D has exploded. DIA continues to lead the way, providing input and insights into the evolution of therapeutic product development, and driving towards improved health and well-being throughout the world. Read On.
Insights
DIA Considerations Guide: Download Now
Developed as part of DIA’s Study of Patient-Centric Initiatives in Drug Development, the Considerations Guide was designed as a practical resource for pharmaceutical companies as you launch or advance patient-centered initiatives that support health care product research and development.
Patient Engagement Study: Download Now
Read this executive summary and detailed study results that include key insights in the following areas: adoption of patient-centric initiatives by pharmaceutical and biotech companies, barriers to adoption of patient-centric initiatives, comparative analytics and results of patient-centric initiatives.
DIA Releases Results of Patient Engagement in Drug Development Study
The DIA study, conducted in partnership with Tufts University, found that half of pharmaceutical and biotech companies surveyed implementing patient-centric drug development initiatives; but measurement and success vary widely. However, barriers such as risk tolerance, lack of staff, time, and budget have constrained implementation. Furthermore, quantifying results is challenging as there is limited comparative analytic data that support specific methods of patient-centricity.
Read the Full Release
Join the Patient Engagement Conversation
DIA Members interact in this exclusive online forum, hosting engaging discussions, webinars and connecting with Patient Engagement stakeholders globally. Already a DIA Member? Visit the DIA Patient Engagement Community.